Abstract library

12 results for "Vitale".
#108 Everolimus (RAD001) induces tumor response in patients with medullary thyroid cancer: an in vivo and in vitro study
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor (NET) of the thyroid C cells which is known to express somatostatin receptors. Octreotide, a somatostatin analogue exerting both antisecretory and antitumor activity in different types of NETs, has shown low efficacy in MTC. Everolimus (RAD001), an inhibitor of mTOR, has shown antitumor effects in patients with NETs and synergistic effects when combined with octreotide. Until recently, RAD001 has never been evaluated in MTC.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Antongiulio Faggiano
#586 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2.
Conference:
Category: Clinical
Presenting Author: Antongiulio Faggiano
#747 A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in Patients with Progressive Medullary Thyroid Cancer (MTC): Preliminary Data
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Valeria Ramundo
#780 Epigenetic Regulation of Endogenous Somatostatin Expression in Neuroendocrine Tumors
Introduction: Somatostatin (SST) can regulate hormone secretion and cell proliferation in neuroendocrine tumors (NETs). SST expression levels in NETs likely differ between patients. DNA methylation inhibits gene transcription and can be reversed by the demethylating drug 5-aza-2-deoxycytidine (AZA).
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: MSc Marije J. Veenstra
#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MSc Marije J Veenstra
Keywords: GEP-NET, sst2, epigenetics
#992 Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Gianluca Tamagno
#1097 Epigenetic Manipulation of the Somatostatin Receptor Type 2 in Neuroendocrine Tumor Cells
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment in patients with neuroendocrine tumors (NET). However, variability in tumoral sst2 expression might lead to variability in response. Epidrugs could increase sst2 levels and improve response to somatostatin analogues (SSA).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Marije Jildau Veenstra
Keywords: NET, sst2, epidrug, signaling
#1127 Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET)
Introduction: Zebrafish is a powerful model to study human diseases, including cancer.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Giovanni Vitale
Keywords: zebrafish, NET
#481 Quality of Life in Patients with Neuroendocrine Tumors: A Cross-Sectional Study
Introduction: Living with cancer affects not only physical and mental health but also the social and professional life of the patient. Measuring quality of life (Qol) is one way to learn from the patient perspective.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MRS Lise Plum
Authors: Plum L, Knigge U, ...
Keywords: quality of life
#487 Validation of Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: CgA is the most important biochemical marker for evaluation of NETs. Different assays with different accuracy exist.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Lise Brehm Høj
Keywords: neuroendocrine, CgA, assay
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.